These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 24784127)

  • 1. Apixaban (eliquis) for stroke prevention in atrial fibrillation.
    Beck RA; King WM
    Am Fam Physician; 2014 Apr; 89(8):672-5. PubMed ID: 24784127
    [No Abstract]   [Full Text] [Related]  

  • 2. Is Apixaban (Eliquis) the "ideal" anticoagulant to replace warfarin for stroke prevention in atrial fibrillation?
    Strain J; Templeton K
    S D Med; 2013 Jan; 66(1):20-1. PubMed ID: 23342716
    [No Abstract]   [Full Text] [Related]  

  • 3. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
    Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
    Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apixaban (Eliquis)--a new oral anticoagulant for atrial fibrillation.
    Med Lett Drugs Ther; 2013 Feb; 55(1409):9-10. PubMed ID: 23381226
    [No Abstract]   [Full Text] [Related]  

  • 5. A review of apixaban for stroke prevention in atrial fibrillation: insights from ARISTOTLE.
    Hess CN; Al-Khatib SM; Granger CB; Lopes R
    Expert Rev Cardiovasc Ther; 2013 Sep; 11(9):1105-14. PubMed ID: 23992517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apixaban for the prevention of stroke in atrial fibrillation.
    Littrell R; Flaker G
    Expert Rev Cardiovasc Ther; 2012 Feb; 10(2):143-9. PubMed ID: 22292869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prevention of stroke in nonvalvular atrial fibrillation. Oral direct factor Xa inhibitor apixaban: positive experiences in general medical practice].
    MMW Fortschr Med; 2013 Sep; 155(16):62-3. PubMed ID: 24279159
    [No Abstract]   [Full Text] [Related]  

  • 8. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
    Lip GY; Larsen TB; Skjøth F; Rasmussen LH
    J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Atrial fibrillation. Apixaban reduces stroke risk].
    MMW Fortschr Med; 2013 Mar; 155(4):70-1. PubMed ID: 23614202
    [No Abstract]   [Full Text] [Related]  

  • 10. Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation.
    Assiri A; Al-Majzoub O; Kanaan AO; Donovan JL; Silva M
    Clin Ther; 2013 Jul; 35(7):967-984.e2. PubMed ID: 23870607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.
    Harenberg J; Marx S; Diener HC; Lip GY; Marder VJ; Wehling M; Weiss C
    Int Angiol; 2012 Aug; 31(4):330-9. PubMed ID: 22801398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation.
    Berman JP; Halperin JL
    Hosp Pract (1995); 2013 Feb; 41(1):37-48. PubMed ID: 23466966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effective anticoagulation also in advanced age].
    Zimmermann W
    MMW Fortschr Med; 2015 Feb; 157(3):72. PubMed ID: 25743684
    [No Abstract]   [Full Text] [Related]  

  • 14. Cost-effectiveness of apixaban compared with aspirin for stroke prevention in atrial fibrillation among patients unsuitable for warfarin.
    Lee S; Anglade MW; Meng J; Hagstrom K; Kluger J; Coleman CI
    Circ Cardiovasc Qual Outcomes; 2012 Jul; 5(4):472-9. PubMed ID: 22740012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential net clinical benefit of population-wide implementation of apixaban and dabigatran among European patients with atrial fibrillation. A modelling analysis from the Euro Heart Survey.
    Pisters R; Nieuwlaat R; Lane DA; Crijns HJ; Lip GY
    Thromb Haemost; 2013 Feb; 109(2):328-36. PubMed ID: 23179181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial.
    Garcia DA; Wallentin L; Lopes RD; Thomas L; Alexander JH; Hylek EM; Ansell J; Hanna M; Lanas F; Flaker G; Commerford P; Xavier D; Vinereanu D; Yang H; Granger CB
    Am Heart J; 2013 Sep; 166(3):549-58. PubMed ID: 24016506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apixaban for stroke prevention in atrial fibrillation: a review of the clinical trial evidence.
    Yates SW
    Hosp Pract (1995); 2011 Oct; 39(4):7-16. PubMed ID: 22056819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-sensitivity troponin T and risk stratification in patients with atrial fibrillation during treatment with apixaban or warfarin.
    Hijazi Z; Wallentin L; Siegbahn A; Andersson U; Alexander JH; Atar D; Gersh BJ; Hanna M; Harjola VP; Horowitz JD; Husted S; Hylek EM; Lopes RD; McMurray JJ; Granger CB;
    J Am Coll Cardiol; 2014 Jan 7-14; 63(1):52-61. PubMed ID: 24055845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
    Mantha S; Ansell J
    Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent advances in antithrombotic therapy for stroke prevention in patients with atrial fibrillation.
    Lenchus JD
    Hosp Pract (1995); 2013 Feb; 41(1):49-60. PubMed ID: 23466967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.